GlassScriptPhysician profile
Allison K Alexander
NPI 1275929481
$1,827.60
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $754 · 2022: $343 · 2023: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $384.54 | 2021-2023 | Farxiga |
| Novo Nordisk INC | $309.91 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $201.44 | 2021-2023 | Mounjaro |
| Amgen INC. | $107.41 | 2021-2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.92 | 2021-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $75.95 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $70.34 | 2021 | |
| Mylan Specialty L.P. | $68.52 | 2021-2023 | Yupelri |
| Abbott Laboratories | $65.37 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.77 | 2021-2023 | Stiolto Respimat |
| Exact Sciences Corporation | $58.46 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $45.34 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $44.04 | 2022-2023 | Rexulti |
| Amarin Pharma, INC. | $32.67 | 2021 | |
| Daiichi Sankyo INC. | $27.76 | 2023 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.50 | 2022 | |
| Bausch Health US, LLC | $21.83 | 2023 | Aplenzin |
| Genentech USA, INC. | $19.19 | 2021 | |
| Eisai INC. | $18.11 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.75 | 2021 | |
| Mannkind Corporation | $15.81 | 2021 | |
| Abbvie INC. | $14.34 | 2023 | |
| Antares Pharma, INC. | $14.16 | 2022 | |
| Pfizer INC. | $13.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.